Enalkiren

CAS: 113082-98-7

Ref. 3D-FE22669

Información del producto

• Nombre: Enalkiren
• Sinónimos: N-(3-Amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide[ 1S-(1R*,2S*,3R*)]-N-(3-Amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhex, (alphaS)-alpha-((alphaS)-alpha-(3-Amino-3-methylbutyramido)-p-methoxyhydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)imidazole-4-propionamide, <span class="text-smallcaps">L</smallcap>-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-<smallcap>L</span>-tyrosyl-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-, <span class="text-smallcaps">L</smallcap>-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-<smallcap>L</span>-tyrosyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-, [1S-(1R*,2S*,3R*)]-, A 64662, Abbott 64662, Enalkiren [USAN:INN], Enalkirene, Enalkirene [INN-French], Enalkirenum, Enalkirenum [INN-Latin], Enalquireno, Enalquireno [INN-Spanish], L-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1S-(1R*,2S*,3R*))-, N-(3-Amino-3-methyl-1-oxobutyl)-O-methyl-<span class="text-smallcaps">L</smallcap>-tyrosyl-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-<smallcap>L</span>-histidinamide, N-(3-amino-3-methylbutanoyl)-O-methyl-L-tyrosyl-N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-L-histidinamide, Unii-0U7Yz42Z47, N-(3-Amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-L-histidinamide, L-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-

Descripción

Enalkiren is a drug that is used to treat congestive heart failure and high blood pressure. It inhibits the renin-angiotensin system by blocking the enzyme angiotensin converting enzyme, which is an important mediator of blood pressure control. Enalkiren has been shown to lower blood pressure in vivo in a model of hypertension with rats. The drug also has low potency and is not bioavailable in humans due to its hydroxyl group and fatty acid side chains. Enalkiren has been shown to have physiological activities such as antihypertensive activity and inhibition of the angiotensin system. The biological sample for this drug includes rat plasma, which may be used to measure the concentration of enalkiren following administration.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 656.86 g/mol
• Fórmula: C₃₅H₅₆N₆O₆
• Pureza: Min. 95%